Background. 
Regardless of mechanism, these clinical observations suggest that treatment decisions for acute infarction patients should be made independently of a history of aspirin use. (Circulation 1991; 84:708-711) L ow-dose aspirin therapy reduces the risk of acute myocardial infarction among patients with a history of myocardial infarction, stroke, or unstable angina as well as among apparently healthy individuals.1-5 In addition to experiencing reduced risk, it is possible that patients suffering infarction while on chronic aspirin therapy have fewer complete coronary occlusions, achieve earlier reperfusion, and sustain smaller infarctions. On the other hand, it is possible that prophylactic aspirin decreases the risk of acute coronary closure but has little effect on the characteristics of infarctions that ultimately occur. Despite the fact that these issues are important for patient management, there are currently no data examining the effects of chronic platelet inhibition with low-dose aspirin on the clinical characteristics of nonfatal myocardial infarction.
In the Physicians' Health Study, 22,071 apparently healthy males 40-84 years old were randomized to 325 mg of alternate-day aspirin (n=11,037) or placebo (n=11,034) therapy and were followed for an average period of 60.2 months. In this report, we describe and compare the size, location, and clinical characteristics of nonfatal myocardial infarctions among those assigned at random to low-dose aspirin with those given placebo. Cardiac catheterization data revealed no statistically significant differences in the percentage of subjects with one-vessel, two-vessel, three-vessel, or left main coronary artery disease. Nearly half of all physicians undergoing peri-infarction catheterization had one-vessel coronary artery disease in both the aspirin and placebo groups. Table 3 presents data for peak CK, CK-MB, and postinfarction left ventricular ejection fraction for the aspirin and placebo groups stratified by age. There was no evidence of effect modification in the relation between aspirin use and these clinical variables when the data were analyzed separately for younger and older patients.
Discussion
Although low-dose aspirin clearly reduces the incidence of first myocardial infarction, the data presented in this report indicate that 325 mg of alternate-day aspirin does not appear to affect the size, anatomic distribution, or functional outcome of events that are survived. Specifically, there were no significant differences in total CK activity or CK-MB fraction between the aspirin and placebo groups. Similarly, there were no significant differences in proportions of Q wave and non-Q wave infarctions or in the distribution of subjects with one-vessel, two-vessel, three-vessel, and left main coronary artery disease. Further, the anatomic distribution of infarction as determined by electrocardiographic analysis showed no evidence that chronic aspirin therapy alters the location of myocardial infarction. Finally, no significant difference in residual left ventricular function after infarction was found between aspirin and placebo groups. For CK, CK-MB, and left ventricular ejection fraction, there was no apparent modification of the overall effect when data were analyzed in various age categories.
The finding that chronic platelet inhibition with low-dose aspirin reduces the incidence of nonfatal infarction but not the clinical characteristics of these events has relevance for patient management. Although the 11,037 men randomized to aspirin suffered 40% fewer nonfatal infarctions than the 11,034 assigned to placebo, the CK and CK-MB levels associated with these infarctions were virtually identical in the two treatment groups. Furthermore Second, although the Physicians' Health Study followed 22,071 individuals over a 5-year period, the possibility that the lack of a significant difference between aspirin and placebo groups is a result of a type II error must be considered. This may be a particular problem for postinfarction left ventricular ejection fraction, where data were not available for a substantial proportion of subjects. Even for this infrequently measured variable, however, the power to assess a 10% change resulting from aspirin therapy was more than 95% (two-sided a, 0.05).
Thus, although data from the Physicians' Health Study demonstrate that alternate-day aspirin reduces the risk of first myocardial infarction, the current analyses also suggest that for survivors of these events, the clinical characteristics of acute infarction are not significantly changed by prior aspirin use. Therefore, the clinical decision to use adjuvant therapies directed at improving coronary patency and ventricular function in the postinfarction period should be made independent of a history of aspirin use.
